title: Lack of interaction of gabapentin with carbamazepine or valproate.
abstract: Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n = 12) or valproate (VPA, n = 14) monotherapy. The effects of GBP coadministration on steady-state CBZ or VPA concentrations and of these antiepileptic drugs (AEDs) on GBP pharmacokinetics were investigated. GBP (400 mg) was coadministered every 8 h for 3 1/3 days with CBZ or for 5 1/3 days with VPA. GBP was well tolerated. Mean steady-state plasma CBZ/CBZ-10,11-epoxide (CBZ-E) and serum VPA concentrations before, during, and after GBP administration were not significantly different. Mean steady-state GBP pharmacokinetic parameters during CBZ or VPA coadministration were similar to steady-state parameters reported in healthy subjects. Thus, no pharmacokinetic interaction exists between CBZ or VPA and GBP. No dosage adjustment is necessary when GBP and CBZ or VPA are coadministered.
authors.affiliation: Department of Pharmacokinetics/Drug Metabolism and Clinical Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan.
authors.forename: L L
authors.initials: LL
authors.lastname: Radulovic
authors.forename: B J
authors.initials: BJ
authors.lastname: Wilder
authors.forename: I E
authors.initials: IE
authors.lastname: Leppik
authors.forename: H N
authors.initials: HN
authors.lastname: Bockbrader
authors.forename: T
authors.initials: T
authors.lastname: Chang
authors.forename: E L
authors.initials: EL
authors.lastname: Posvar
authors.forename: A J
authors.initials: AJ
authors.lastname: Sedman
authors.forename: B M
authors.initials: BM
authors.lastname: Uthman
authors.forename: G R
authors.initials: GR
authors.lastname: Erdman
mesh_terms: D000085:Acetates / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D014635:Valproic Acid / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; C012227:carbamazepine epoxide